Get the Stockscreener App
6.39
1.24%
-0.08
Pre-market:
6.58
0.19
+2.97%
Harvard Bioscience Inc stock is traded at $6.39, with a volume of 38,813.
It is down -1.24% in the last 24 hours and up +4.07% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
See More
Previous Close:
$6.47
Open:
$6.35
24h Volume:
38,813
Relative Volume:
1.73
Market Cap:
$28.82M
Revenue:
$85.53M
Net Income/Loss:
$-9.78M
P/E Ratio:
-2.9109
EPS:
-2.1952
Net Cash Flow:
$1.28M
1W Performance:
+1.27%
1M Performance:
+4.07%
6M Performance:
+6.32%
1Y Performance:
+21.07%
1-Day Range:
$6.205
$6.68
1-Week Range:
$6.02
$6.68
52-Week Range:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
6.39 | 27.02M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
393.38 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.63 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
73.63 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
220.05 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.81 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Harvard Bioscience Q2 Results: Earnings Call Set for August 11 - scanx.trade
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET - The Manila Times
Harvard Bioscience to release quarter results before market opens Aug. 11 - Stock Titan
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harvard Bioscience Inc (HBIO) Cash Flow - TradingKey
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HBIO|Harvard Bioscience Inc|Price:6.000|Chg%:-0.190 - TradingKey
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience, Inc. Revenue Breakdown – MUN:HBI0 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LS:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – NASDAQ:HBIO - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LSX:A423J5 - TradingView
HBIO Stock Price, Quote & Chart - ChartMill
HBIO Q2'26 Earnings: revenue estimate is 21.45M USD - TradingView
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de
Harvard Bioscience focuses on lab equipment growth - Ad-hoc-news.de
Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume TradingBollinger Walk - dars.gov.et
Harvard Bioscience | SD: Specialized disclosure report - Moomoo
Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView
HBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to earnings forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to book forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Enterprise value to EBITDA forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harvard Bioscience (HBIO) Slips Slightly, Holding Above Support at $5.71Quality Factor - dars.gov.et
Harvard Bioscience holds key trading range, shares between support and resistance - AD HOC NEWS
HBIO News | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience Inc (HBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 RSUs in new grant - Stock Titan
Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs - Stock Titan
HBIO Q1 2026 Earnings: Significant EPS Beat Drives Positive Stock ReactionMid-Term Outlook - dars.gov.et
Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results - Moomoo
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors - TipRanks
Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases - Stock Titan
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
Harvard Bioscience (HBIO) Edges Lower Amid Modest Selling Pressure – Key Support Levels in FocusOn Balance Volume - dars.gov.et
HBIOHarvard Bioscience Inc Website Traffic and Mobile Apps Usage - Finviz
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
QTEX Stock Price and Chart — NASDAQ:QTEX - TradingView
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harvard Bioscience Inc Stock (HBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director |
Mar 17 '26 |
Buy |
4.87 |
10,000 |
48,700 |
21,000 |
| Snider William | Director |
Mar 16 '26 |
Buy |
4.99 |
12,525 |
62,500 |
23,525 |
| Snider William | Director |
Mar 17 '26 |
Buy |
4.85 |
8,475 |
41,104 |
32,000 |
| Duke John D | Chief Executive Officer |
Mar 16 '26 |
Buy |
5.01 |
5,000 |
25,050 |
105,000 |
1.37%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):